Abstract
Daiichi Sankyo will close its research unit in Gurgaon, near New Delhi, India. The move will affect 170 people, most of whom are researchers focused on infectious disease and inflammation. Last February, Daiichi closed its R&D center in Gerrards Cross, England, a move that impacted 80 people. The Indian research unit is a legacy from Daiichi’s 2008 acquisition of Ranbaxy Laboratories. When Daiichi Sankyo sold Ranbaxy to Sun Pharmaceutical Industries in 2015, it retained the operation as a separate subsidiary.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
